Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 04, 2021

SELL
$132.37 - $176.78 $231,647 - $309,365
-1,750 Closed
0 $0
Q2 2021

Jul 29, 2021

BUY
$60.88 - $161.91 $106,540 - $283,342
1,750 New
1,750 $283,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.08B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Chase Investment Counsel Corp Portfolio

Follow Chase Investment Counsel Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chase Investment Counsel Corp, based on Form 13F filings with the SEC.

News

Stay updated on Chase Investment Counsel Corp with notifications on news.